On November 13, 2025, Kura Oncology, Inc. announced FDA approval of KOMZIFTI for adult patients with relapsed or refractory acute myeloid leukemia, priced at $48,500 per month. This is the first oral menin inhibitor for a specific mutation in leukemia, addressing an urgent need for treatment with a 21.4% remission rate in trials.